These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

759 related items for PubMed ID: 16249018

  • 1. HPV16/18 E7-pulsed dendritic cell vaccination in cervical cancer patients with recurrent disease refractory to standard treatment modalities.
    Santin AD, Bellone S, Palmieri M, Ravaggi A, Romani C, Tassi R, Roman JJ, Burnett A, Pecorelli S, Cannon MJ.
    Gynecol Oncol; 2006 Mar; 100(3):469-78. PubMed ID: 16249018
    [Abstract] [Full Text] [Related]

  • 2. Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine.
    Welters MJ, Kenter GG, Piersma SJ, Vloon AP, Löwik MJ, Berends-van der Meer DM, Drijfhout JW, Valentijn AR, Wafelman AR, Oostendorp J, Fleuren GJ, Offringa R, Melief CJ, van der Burg SH.
    Clin Cancer Res; 2008 Jan 01; 14(1):178-87. PubMed ID: 18172269
    [Abstract] [Full Text] [Related]

  • 3. Advances in dendritic-cell-based therapeutic vaccines for cervical cancer.
    Bellone S, Pecorelli S, Cannon MJ, Santin AD.
    Expert Rev Anticancer Ther; 2007 Oct 01; 7(10):1473-86. PubMed ID: 17944571
    [Abstract] [Full Text] [Related]

  • 4. Human papillomavirus type 16 and 18 E7-pulsed dendritic cell vaccination of stage IB or IIA cervical cancer patients: a phase I escalating-dose trial.
    Santin AD, Bellone S, Palmieri M, Zanolini A, Ravaggi A, Siegel ER, Roman JJ, Pecorelli S, Cannon MJ.
    J Virol; 2008 Feb 01; 82(4):1968-79. PubMed ID: 18057249
    [Abstract] [Full Text] [Related]

  • 5. Cell-mediated immunological responses in cervical and vaginal cancer patients immunized with a lipidated epitope of human papillomavirus type 16 E7.
    Steller MA, Gurski KJ, Murakami M, Daniel RW, Shah KV, Celis E, Sette A, Trimble EL, Park RC, Marincola FM.
    Clin Cancer Res; 1998 Sep 01; 4(9):2103-9. PubMed ID: 9748126
    [Abstract] [Full Text] [Related]

  • 6. Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity.
    Kenter GG, Welters MJ, Valentijn AR, Lowik MJ, Berends-van der Meer DM, Vloon AP, Drijfhout JW, Wafelman AR, Oostendorp J, Fleuren GJ, Offringa R, van der Burg SH, Melief CJ.
    Clin Cancer Res; 2008 Jan 01; 14(1):169-77. PubMed ID: 18172268
    [Abstract] [Full Text] [Related]

  • 7. HPV16E7 tumor antigen modified by KDEL sequence induce specific cytotoxic T lymphocytes-dependent antitumor immunity.
    Yin R, Zheng W, Hao F, Yang XC, Zhong BY, Li QJ.
    J Dermatol Sci; 2009 Aug 01; 55(2):116-22. PubMed ID: 19500947
    [Abstract] [Full Text] [Related]

  • 8. Induction of tumor-specific cytotoxicity in tumor infiltrating lymphocytes by HPV16 and HPV18 E7-pulsed autologous dendritic cells in patients with cancer of the uterine cervix.
    Santin AD, Bellone S, Palmieri M, Bossini B, Roman JJ, Cannon MJ, Bignotti E, Canè S, Pecorelli S.
    Gynecol Oncol; 2003 May 01; 89(2):271-80. PubMed ID: 12713991
    [Abstract] [Full Text] [Related]

  • 9. Immunization with human papillomavirus type 16 (HPV16) oncoprotein-loaded dendritic cells as well as protein in adjuvant induces MHC class I-restricted protection to HPV16-induced tumor cells.
    De Bruijn ML, Schuurhuis DH, Vierboom MP, Vermeulen H, de Cock KA, Ooms ME, Ressing ME, Toebes M, Franken KL, Drijfhout JW, Ottenhoff TH, Offringa R, Melief CJ.
    Cancer Res; 1998 Feb 15; 58(4):724-31. PubMed ID: 9485027
    [Abstract] [Full Text] [Related]

  • 10. Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma.
    Yu JS, Liu G, Ying H, Yong WH, Black KL, Wheeler CJ.
    Cancer Res; 2004 Jul 15; 64(14):4973-9. PubMed ID: 15256471
    [Abstract] [Full Text] [Related]

  • 11. Correlation between serological immune response analyzed by a new ELISA for HPV-16/18 E7 oncoprotein and clinical characteristics of cervical cancer patients.
    Ravaggi A, Romani C, Pasinetti B, Tassi RA, Bignotti E, Bandiera E, Odicino FE, Ragnoli M, Donzelli C, Falchetti M, Calza S, Santin AD, Pecorelli S.
    Arch Virol; 2006 Oct 15; 151(10):1899-916. PubMed ID: 16732494
    [Abstract] [Full Text] [Related]

  • 12. Disease-stage variance in functional CD4(+) T-cell responses against novel pan-human leukocyte antigen-D region presented human papillomavirus-16 E7 epitopes.
    Warrino DE, Olson WC, Knapp WT, Scarrow MI, D'Ambrosio-Brennan LJ, Guido RS, Edwards RP, Kast WM, Storkus WJ.
    Clin Cancer Res; 2004 May 15; 10(10):3301-8. PubMed ID: 15161683
    [Abstract] [Full Text] [Related]

  • 13. Dendritic cell-based tumor vaccine for cervical cancer II: results of a clinical pilot study in 15 individual patients.
    Ferrara A, Nonn M, Sehr P, Schreckenberger C, Pawlita M, Dürst M, Schneider A, Kaufmann AM.
    J Cancer Res Clin Oncol; 2003 Sep 15; 129(9):521-30. PubMed ID: 12898233
    [Abstract] [Full Text] [Related]

  • 14. Analysis and characterization of antitumor T-cell response after administration of dendritic cells loaded with allogeneic tumor lysate to metastatic melanoma patients.
    Bercovici N, Haicheur N, Massicard S, Vernel-Pauillac F, Adotevi O, Landais D, Gorin I, Robert C, Prince HM, Grob JJ, Leccia MT, Lesimple T, Wijdenes J, Bartholeyns J, Fridman WH, Salcedo M, Ferries E, Tartour E.
    J Immunother; 2008 Jan 15; 31(1):101-12. PubMed ID: 18157017
    [Abstract] [Full Text] [Related]

  • 15. Immunological and clinical responses in women with vulval intraepithelial neoplasia vaccinated with a vaccinia virus encoding human papillomavirus 16/18 oncoproteins.
    Davidson EJ, Boswell CM, Sehr P, Pawlita M, Tomlinson AE, McVey RJ, Dobson J, Roberts JS, Hickling J, Kitchener HC, Stern PL.
    Cancer Res; 2003 Sep 15; 63(18):6032-41. PubMed ID: 14522932
    [Abstract] [Full Text] [Related]

  • 16. Immunohistological analysis of peptide-induced delayed-type hypersensitivity in advanced melanoma patients treated with melanoma antigen-pulsed mature monocyte-derived dendritic cell vaccination.
    Nakai N, Katoh N, Germeraad WT, Kishida T, Ueda E, Takenaka H, Mazda O, Kishimoto S.
    J Dermatol Sci; 2009 Jan 15; 53(1):40-7. PubMed ID: 18804963
    [Abstract] [Full Text] [Related]

  • 17. HPV16-specific cytotoxic T lymphocyte responses are detected in all HPV16-positive cervical cancer patients.
    Valdespino V, Gorodezky C, Ortiz V, Kaufmann AM, Roman-Basaure E, Vazquez A, Berumen J.
    Gynecol Oncol; 2005 Jan 15; 96(1):92-102. PubMed ID: 15589586
    [Abstract] [Full Text] [Related]

  • 18. Dendritic cell-based tumor vaccine for cervical cancer I: in vitro stimulation with recombinant protein-pulsed dendritic cells induces specific T cells to HPV16 E7 or HPV18 E7.
    Nonn M, Schinz M, Zumbach K, Pawlita M, Schneider A, Dürst M, Kaufmann AM.
    J Cancer Res Clin Oncol; 2003 Sep 15; 129(9):511-20. PubMed ID: 12905010
    [Abstract] [Full Text] [Related]

  • 19. Generation of tumor-specific cytotoxic T lymphocytes by stimulation with HPV type 16 E7 peptide-pulsed dendritic cells: an approach to immunotherapy of cervical cancer.
    Schoell WM, Mirhashemi R, Liu B, Janicek MF, Podack ER, Penalver MA, Averette HE.
    Gynecol Oncol; 1999 Sep 15; 74(3):448-55. PubMed ID: 10479508
    [Abstract] [Full Text] [Related]

  • 20. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.
    Palucka AK, Ueno H, Connolly J, Kerneis-Norvell F, Blanck JP, Johnston DA, Fay J, Banchereau J.
    J Immunother; 2006 Sep 15; 29(5):545-57. PubMed ID: 16971810
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 38.